Literature DB >> 10403651

One of two unstructured domains of Ii becomes ordered in complexes with MHC class II molecules.

A Jasanoff1, S Song, A R Dinner, G Wagner, D C Wiley.   

Abstract

We studied the role of the invariant chain (Ii) protein's structure in its ability to form complexes with major histocompatibility complex class II molecules. Multidimensional nuclear magnetic resonance experiments demonstrated that Ii contains two unstructured, flexible domains: a 39 residue sequence that contains a region (CLIP) critical for Ii/class II complex formation and becomes rapidly ordered when Ii/class II complexes are assembled, and a 30 residue sequence that contains the insertion point for a protease inhibitor domain included in an alternative splice form of Ii. Mobility of these domains guarantees accessibility to CLIP and the inhibitor insert, and ordering of the CLIP-containing domain may provide protection against proteolysis and contribute, along with Ii's compact 118-192 domain, to allotype-independent class II binding.

Mesh:

Substances:

Year:  1999        PMID: 10403651     DOI: 10.1016/s1074-7613(00)80075-8

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  11 in total

1.  Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes.

Authors:  F Bischof; W Wienhold; C Wirblich; G Malcherek; O Zevering; A M Kruisbeek; A Melms
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

2.  A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.

Authors:  Arthur A Vandenbark; Roberto Meza-Romero; Gil Benedek; Shayne Andrew; Jianya Huan; Yuan K Chou; Abigail C Buenafe; Rony Dahan; Yoram Reiter; Jeffery L Mooney; Halina Offner; Gregory G Burrows
Journal:  J Autoimmun       Date:  2012-09-29       Impact factor: 7.094

3.  MIF and D-DT are potential disease severity modifiers in male MS subjects.

Authors:  Gil Benedek; Roberto Meza-Romero; Kelley Jordan; Ying Zhang; Ha Nguyen; Gail Kent; Jia Li; Edwin Siu; Jenny Frazer; Marta Piecychna; Xin Du; Antoine Sreih; Lin Leng; Jack Wiedrick; Stacy J Caillier; Halina Offner; Jorge R Oksenberg; Vijayshree Yadav; Dennis Bourdette; Richard Bucala; Arthur A Vandenbark
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

Review 4.  The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis.

Authors:  Gil Benedek; Roberto Meza-Romero; Dennis Bourdette; Arthur A Vandenbark
Journal:  Metab Brain Dis       Date:  2014-12-12       Impact factor: 3.584

5.  Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74.

Authors:  Roberto Meza-Romero; Gil Benedek; Kelley Jordan; Lin Leng; Georgios Pantouris; Elias Lolis; Richard Bucala; Arthur A Vandenbark
Journal:  Cytokine       Date:  2016-08-27       Impact factor: 3.861

6.  Stoichiometry of HLA class II-invariant chain oligomers.

Authors:  Norbert Koch; Martin Zacharias; Angelika König; Sebastian Temme; Jürgen Neumann; Sebastian Springer
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

Review 7.  Partnering for the major histocompatibility complex class II and antigenic determinant requires flexibility and chaperons.

Authors:  Scheherazade Sadegh-Nasseri
Journal:  Curr Opin Immunol       Date:  2021-06-17       Impact factor: 7.268

Review 8.  Invariant Chain Complexes and Clusters as Platforms for MIF Signaling.

Authors:  Robert Lindner
Journal:  Cells       Date:  2017-02-10       Impact factor: 6.600

Review 9.  Exposing the Specific Roles of the Invariant Chain Isoforms in Shaping the MHC Class II Peptidome.

Authors:  Jean-Simon Fortin; Maryse Cloutier; Jacques Thibodeau
Journal:  Front Immunol       Date:  2013-12-13       Impact factor: 7.561

Review 10.  A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells.

Authors:  Scheherazade Sadegh-Nasseri
Journal:  F1000Res       Date:  2016-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.